Patient-related outcomes for metastatic prostate cancer
Mené sur 1 717 patients atteints d'un cancer métastatique de la prostate résistant à la castration, cet essai randomisé de phase III évalue les effets de l'enzalutamide sur des indicateurs de qualité de vie et de douleur ainsi que sur le délai avant la survenue d'un premier événement osseux
Pain, fatigue, functional impairment, and diminished health-related quality of life (HRQoL) are common among men with metastatic castration-resistant prostate cancer. Measurement of these important patient-related outcomes has played a prominent part in drug development for this disease in the past 20 years (dating back to the approval of mitoxantrone in 1996) and is now considered a standard component of clinical research in metastatic castration-resistant prostate cancer.